Convalescent transfusion for pandemic influenza: Preparing blood banks for a new plasma product?

Research output: Contribution to journalArticle

Abstract

Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral- and vaccine-based response to an influenza pandemic. One such countermeasure - the transfusion of pandemic influenza-specific antibodies from surviving patients to the clinically ill - is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP-Flu]) are discussed. FCP-Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP-Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.

Original languageEnglish (US)
Pages (from-to)1384-1398
Number of pages15
JournalTransfusion
Volume50
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Blood Banks
Pandemics
Human Influenza
Passive Immunization
Globulins
Blood Donors
Antiviral Agents
Allografts
Vaccines
Monoclonal Antibodies
Research Personnel
Anti-Bacterial Agents
Safety
Antibodies
Research

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy

Cite this

Convalescent transfusion for pandemic influenza : Preparing blood banks for a new plasma product? / Leider, Jonathon P.; Brunker, Patricia Ann Ramaley; Ness, Paul Michael.

In: Transfusion, Vol. 50, No. 6, 06.2010, p. 1384-1398.

Research output: Contribution to journalArticle

@article{2c49417e72e245bbb068a449ef2c028a,
title = "Convalescent transfusion for pandemic influenza: Preparing blood banks for a new plasma product?",
abstract = "Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral- and vaccine-based response to an influenza pandemic. One such countermeasure - the transfusion of pandemic influenza-specific antibodies from surviving patients to the clinically ill - is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP-Flu]) are discussed. FCP-Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP-Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.",
author = "Leider, {Jonathon P.} and Brunker, {Patricia Ann Ramaley} and Ness, {Paul Michael}",
year = "2010",
month = "6",
doi = "10.1111/j.1537-2995.2010.02590.x",
language = "English (US)",
volume = "50",
pages = "1384--1398",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Convalescent transfusion for pandemic influenza

T2 - Preparing blood banks for a new plasma product?

AU - Leider, Jonathon P.

AU - Brunker, Patricia Ann Ramaley

AU - Ness, Paul Michael

PY - 2010/6

Y1 - 2010/6

N2 - Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral- and vaccine-based response to an influenza pandemic. One such countermeasure - the transfusion of pandemic influenza-specific antibodies from surviving patients to the clinically ill - is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP-Flu]) are discussed. FCP-Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP-Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.

AB - Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral- and vaccine-based response to an influenza pandemic. One such countermeasure - the transfusion of pandemic influenza-specific antibodies from surviving patients to the clinically ill - is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP-Flu]) are discussed. FCP-Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP-Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.

UR - http://www.scopus.com/inward/record.url?scp=77953085882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953085882&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2010.02590.x

DO - 10.1111/j.1537-2995.2010.02590.x

M3 - Article

C2 - 20158681

AN - SCOPUS:77953085882

VL - 50

SP - 1384

EP - 1398

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 6

ER -